-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下： HII公布第一季度营收为31亿美元，同比增长13.4%，超出市场预期2.7%。尽管营收增长，但营业利润率却下降了89个基点至5.0%。第一季度每股收益为3.79美元，与上年持平，超出市场预期0.08美元。这些业绩凸显了我们一直关注的一个矛盾：虽然营收增长证实了良好的市场需求，但实现9%-10%的造船利润率目标的路径比预期更为缓慢。管理层重申了2026财年的业绩指引，预计造船营收为97亿至99亿美元，营业利润率为5.5%-6.5%，自由现金流为5亿至6亿美元。纽波特纽斯公司营收增长19.3%至17亿美元，推动公司整体增长，但由于缺乏有利的弗吉尼亚州级合同调整，该部门利润率下降80个基点至5.3%。自由现金流仍为负值，为4.61亿美元。我们认为，即将授予的弗吉尼亚州第六区块和哥伦比亚二期建设项目合同仍是关键的推动因素，因为这些合同应能反映当前的成本结构，并有助于在未来的工作中获得更高的利润率。
Related Articles
Commodities
Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand
Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%
$AVA
Australia
Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says
Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%
$PRMB
Australia
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%
$BMRN$FOLD